Elcubragistat - Lundbeck A/S
Alternative Names: ABX-1431; ABX-1431 HCl; Lu AG06466Latest Information Update: 28 Sep 2024
At a glance
- Originator Abide Therapeutics
- Developer Abide Therapeutics; Lundbeck A/S; University of Oxford
- Class Analgesics; Antiepileptic drugs; Anxiolytics; Benzene derivatives; Esters; Fluorinated hydrocarbons; Piperazines; Pyrrolidines; Small molecules
- Mechanism of Action Monoacylglycerol lipase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Muscle spasticity; Partial epilepsies; Unspecified
- No development reported Fibromyalgia; Neurological disorders; Neuropathic pain; Non-ulcer dyspepsia; Pain; Post-traumatic stress disorders
- Discontinued Gilles de la Tourette's syndrome
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Neurological-disorders(In volunteers) in United Kingdom (PO, Tablet)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Fibromyalgia in USA (PO, Capsule)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Post-traumatic-stress-disorders in USA (PO, Capsule)